$RVMD Presents OS Data for RASONQUE Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at #ESMO26 $TNGX

The subgroup analyses showed RASONQUE consistently provided an OS benefit across key subgroups, including patients with no identified tumor RAS mutation​

https://www.globenewswire.com/news-release/2026/10/23/3387179/0/en/revolution-medicines-presents-overall-survival-data-for-rasonque-daraxonrasib-across-subgroups-in-previously-treated-metastatic-pancreatic-cancer-at-esmo-2026.html